EGFR kinase inhibitors and gastric acid suppressants in EGFR-mutant NSCLC: A retrospective database analysis of potential drug interaction

10.18632/oncotarget.13458

Saved in:

Bibliographic Details
Main Authors:	Kumarakulasinghe, N.B, Syn, N, Soon, Y.Y, Asmat, A, Zheng, H, Loy, E.Y, Pang, B, Soo, R.A
Other Authors:	PATHOLOGY
Format:	Article
Published:	Impact Journals LLC 2020
Subjects:	erlotinib gefitinib histamine H2 receptor antagonist proton pump inhibitor antineoplastic agent EGFR protein, human epidermal growth factor receptor protein kinase inhibitor quinazoline derivative adult aged Article cancer chemotherapy Charlson Comorbidity Index cohort analysis controlled study drug antagonism drug use EGFR gene female gene mutation human Karnofsky Performance Status major clinical study male medical record review non small cell lung cancer overall survival progression free survival receptor gene antagonists and inhibitors chi square distribution clinical trial disease exacerbation disease free survival drug interaction enzymology factual database genetics Kaplan Meier method lung tumor metabolism middle aged mortality multicenter study multivariate analysis mutation proportional hazards model retrospective study risk assessment risk factor Singapore time factor treatment outcome very elderly Adult Aged Aged, 80 and over Antineoplastic Agents Carcinoma, Non-Small-Cell Lung Chi-Square Distribution Databases, Factual Disease Progression Disease-Free Survival Drug Interactions Erlotinib Hydrochloride Female Humans Kaplan-Meier Estimate Lung Neoplasms Male Middle Aged Multivariate Analysis Mutation Proportional Hazards Models Protein Kinase Inhibitors Proton Pump Inhibitors Quinazolines Receptor, Epidermal Growth Factor Retrospective Studies Risk Assessment Risk Factors Time Factors Treatment Outcome
Online Access:	https://scholarbank.nus.edu.sg/handle/10635/175449
Tags:	Add Tag No Tags, Be the first to tag this record!
Institution:	National University of Singapore

id	sg-nus-scholar.10635-175449
record_format	dspace
spelling	sg-nus-scholar.10635-1754492024-04-03T07:38:00Z EGFR kinase inhibitors and gastric acid suppressants in EGFR-mutant NSCLC: A retrospective database analysis of potential drug interaction Kumarakulasinghe, N.B Syn, N Soon, Y.Y Asmat, A Zheng, H Loy, E.Y Pang, B Soo, R.A PATHOLOGY CANCER SCIENCE INSTITUTE OF SINGAPORE erlotinib gefitinib histamine H2 receptor antagonist proton pump inhibitor antineoplastic agent EGFR protein, human epidermal growth factor receptor erlotinib gefitinib protein kinase inhibitor proton pump inhibitor quinazoline derivative adult aged Article cancer chemotherapy Charlson Comorbidity Index cohort analysis controlled study drug antagonism drug use EGFR gene female gene mutation human Karnofsky Performance Status major clinical study male medical record review non small cell lung cancer overall survival progression free survival receptor gene antagonists and inhibitors chi square distribution clinical trial disease exacerbation disease free survival drug interaction enzymology factual database genetics Kaplan Meier method lung tumor metabolism middle aged mortality multicenter study multivariate analysis mutation non small cell lung cancer proportional hazards model retrospective study risk assessment risk factor Singapore time factor treatment outcome very elderly Adult Aged Aged, 80 and over Antineoplastic Agents Carcinoma, Non-Small-Cell Lung Chi-Square Distribution Databases, Factual Disease Progression Disease-Free Survival Drug Interactions Erlotinib Hydrochloride Female Humans Kaplan-Meier Estimate Karnofsky Performance Status Lung Neoplasms Male Middle Aged Multivariate Analysis Mutation Proportional Hazards Models Protein Kinase Inhibitors Proton Pump Inhibitors Quinazolines Receptor, Epidermal Growth Factor Retrospective Studies Risk Assessment Risk Factors Singapore Time Factors Treatment Outcome 10.18632/oncotarget.13458 Oncotarget 7 51 85542-85550 2020-09-10T01:43:40Z 2020-09-10T01:43:40Z 2016 Article Kumarakulasinghe, N.B, Syn, N, Soon, Y.Y, Asmat, A, Zheng, H, Loy, E.Y, Pang, B, Soo, R.A (2016). EGFR kinase inhibitors and gastric acid suppressants in EGFR-mutant NSCLC: A retrospective database analysis of potential drug interaction. Oncotarget 7 (51) : 85542-85550. ScholarBank@NUS Repository. https://doi.org/10.18632/oncotarget.13458 19492553 https://scholarbank.nus.edu.sg/handle/10635/175449 Impact Journals LLC Unpaywall 20200831
institution	National University of Singapore
building	NUS Library
continent	Asia
country	Singapore Singapore
content_provider	NUS Library
collection	ScholarBank@NUS
topic	erlotinib gefitinib histamine H2 receptor antagonist proton pump inhibitor antineoplastic agent EGFR protein, human epidermal growth factor receptor erlotinib gefitinib protein kinase inhibitor proton pump inhibitor quinazoline derivative adult aged Article cancer chemotherapy Charlson Comorbidity Index cohort analysis controlled study drug antagonism drug use EGFR gene female gene mutation human Karnofsky Performance Status major clinical study male medical record review non small cell lung cancer overall survival progression free survival receptor gene antagonists and inhibitors chi square distribution clinical trial disease exacerbation disease free survival drug interaction enzymology factual database genetics Kaplan Meier method lung tumor metabolism middle aged mortality multicenter study multivariate analysis mutation non small cell lung cancer proportional hazards model retrospective study risk assessment risk factor Singapore time factor treatment outcome very elderly Adult Aged Aged, 80 and over Antineoplastic Agents Carcinoma, Non-Small-Cell Lung Chi-Square Distribution Databases, Factual Disease Progression Disease-Free Survival Drug Interactions Erlotinib Hydrochloride Female Humans Kaplan-Meier Estimate Karnofsky Performance Status Lung Neoplasms Male Middle Aged Multivariate Analysis Mutation Proportional Hazards Models Protein Kinase Inhibitors Proton Pump Inhibitors Quinazolines Receptor, Epidermal Growth Factor Retrospective Studies Risk Assessment Risk Factors Singapore Time Factors Treatment Outcome
spellingShingle	erlotinib gefitinib histamine H2 receptor antagonist proton pump inhibitor antineoplastic agent EGFR protein, human epidermal growth factor receptor erlotinib gefitinib protein kinase inhibitor proton pump inhibitor quinazoline derivative adult aged Article cancer chemotherapy Charlson Comorbidity Index cohort analysis controlled study drug antagonism drug use EGFR gene female gene mutation human Karnofsky Performance Status major clinical study male medical record review non small cell lung cancer overall survival progression free survival receptor gene antagonists and inhibitors chi square distribution clinical trial disease exacerbation disease free survival drug interaction enzymology factual database genetics Kaplan Meier method lung tumor metabolism middle aged mortality multicenter study multivariate analysis mutation non small cell lung cancer proportional hazards model retrospective study risk assessment risk factor Singapore time factor treatment outcome very elderly Adult Aged Aged, 80 and over Antineoplastic Agents Carcinoma, Non-Small-Cell Lung Chi-Square Distribution Databases, Factual Disease Progression Disease-Free Survival Drug Interactions Erlotinib Hydrochloride Female Humans Kaplan-Meier Estimate Karnofsky Performance Status Lung Neoplasms Male Middle Aged Multivariate Analysis Mutation Proportional Hazards Models Protein Kinase Inhibitors Proton Pump Inhibitors Quinazolines Receptor, Epidermal Growth Factor Retrospective Studies Risk Assessment Risk Factors Singapore Time Factors Treatment Outcome Kumarakulasinghe, N.B Syn, N Soon, Y.Y Asmat, A Zheng, H Loy, E.Y Pang, B Soo, R.A EGFR kinase inhibitors and gastric acid suppressants in EGFR-mutant NSCLC: A retrospective database analysis of potential drug interaction
description	10.18632/oncotarget.13458
author2	PATHOLOGY
author_facet	PATHOLOGY Kumarakulasinghe, N.B Syn, N Soon, Y.Y Asmat, A Zheng, H Loy, E.Y Pang, B Soo, R.A
format	Article
author	Kumarakulasinghe, N.B Syn, N Soon, Y.Y Asmat, A Zheng, H Loy, E.Y Pang, B Soo, R.A
author_sort	Kumarakulasinghe, N.B
title	EGFR kinase inhibitors and gastric acid suppressants in EGFR-mutant NSCLC: A retrospective database analysis of potential drug interaction
title_short	EGFR kinase inhibitors and gastric acid suppressants in EGFR-mutant NSCLC: A retrospective database analysis of potential drug interaction
title_full	EGFR kinase inhibitors and gastric acid suppressants in EGFR-mutant NSCLC: A retrospective database analysis of potential drug interaction
title_fullStr	EGFR kinase inhibitors and gastric acid suppressants in EGFR-mutant NSCLC: A retrospective database analysis of potential drug interaction
title_full_unstemmed	EGFR kinase inhibitors and gastric acid suppressants in EGFR-mutant NSCLC: A retrospective database analysis of potential drug interaction
title_sort	egfr kinase inhibitors and gastric acid suppressants in egfr-mutant nsclc: a retrospective database analysis of potential drug interaction
publisher	Impact Journals LLC
publishDate	2020
url	https://scholarbank.nus.edu.sg/handle/10635/175449
_version_	1795374381098074112

EGFR kinase inhibitors and gastric acid suppressants in EGFR-mutant NSCLC: A retrospective database analysis of potential drug interaction

Similar Items